Contact
Please use this form to send email to PR contact of this press release:
First Participant Dosed in Phase 1 Clinical Study with VTP-300 Immunotherapeutic to Treat Chronically Infected Hepatitis B Patients
TO:
Please use this form to send email to PR contact of this press release:
First Participant Dosed in Phase 1 Clinical Study with VTP-300 Immunotherapeutic to Treat Chronically Infected Hepatitis B Patients
TO: